SpringWorks Hopes Pediatric Plus Adult Data Make Mirdametinib Go-To For NF1-PN

 
• By Alaric DeArment
SpringWorks announced data from its Phase IIb trial of mirdametinib in the rare disease NF1. • Source: Shutterstock

More from Clinical Trials

More from R&D